These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10179705)

  • 1. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.
    Anis AH; Hogg RS; Wang XH; Yip B; Palepu A; Montaner JS; O'Shaughnessy MV; Schechter MT
    Pharmacoeconomics; 1998 Jun; 13(6):697-705. PubMed ID: 10179705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women.
    Anis AH; Hogg RS; Yip B; Wang XH; Montaner JS; O'Shaughnessy MV; Schechter MT
    Pharmacoeconomics; 1998 Mar; 13(3):327-36. PubMed ID: 10178658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
    AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
    Floridia M; Massella M; Bucciardini R; Perucci CA; Rossi L; Tomino C; Fragola V; Ricciardulli D; Galluzzo CM; Giannini G; Pirillo MF; Andreotti M; Mirra M; Vella S
    HIV Clin Trials; 2000; 1(2):9-16. PubMed ID: 11590493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One world, one hope: the cost of providing antiretroviral therapy to all nations.
    Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
    AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.
    Oddershede L; Walker S; Stöhr W; Dunn DT; Arenas-Pinto A; Paton NI; Sculpher M;
    Pharmacoeconomics; 2016 Aug; 34(8):795-804. PubMed ID: 26966125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
    Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
    Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS.
    Anis AH; Guh D; Hogg RS; Wang XH; Yip B; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
    Pharmacoeconomics; 2000 Oct; 18(4):393-404. PubMed ID: 15344307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
    Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
    CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
    Int J STD AIDS; 1999 Jun; 10(6):357-62. PubMed ID: 10414877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.
    Caro JJ; O'Brien JA; Migliaccio-Walle K; Raggio G
    Pharmacoeconomics; 2001 Jan; 19(1):95-104. PubMed ID: 11252549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of HIV medical care in the era of highly active antiretroviral therapy.
    Gebo KA; Chaisson RE; Folkemer JG; Bartlett JG; Moore RD
    AIDS; 1999 May; 13(8):963-9. PubMed ID: 10371178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.